ABIN262786

antibody from antibodies-online

Targeting: HLA-DRA HLA-DRA1

Provider product page for ABIN262786

Western blot

Immunoprecipitation

Immunohistochemistry

Flow cytometry

Antibody data

Antibody Data
Antigen structure
References [26]
Comments [0]
Validations
Western blot [1]
Immunohistochemistry [1]
Flow cytometry [6]

Submit

Product number: ABIN262786 - Provider product page
Provider: antibodies-online
Product name: anti-HLA-DR (HLA-DR) antibody
Antibody type: Monoclonal
Description: Protein A purified
Reactivity: Human, Canine, Simian
Host: Mouse
Isotype: IgG
Antibody clone number: L243
Vial size: 0.1 mL
Storage: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
Handling: Do not freeze.

HLA-DRA protein structure - ABIN262786 shown in red.

Submitted references The role of tetraspanin CD63 in antigen presentation via MHC class II.

Petersen SH, Odintsova E, Haigh TA, Rickinson AB, Taylor GS, Berditchevski F
European journal of immunology 2011 Sep;41(9):2556-61

Human leucocyte antigen (HLA) expression of primary trophoblast cells and placental cell lines, determined using single antigen beads to characterize allotype specificities of anti-HLA antibodies.

Apps R, Murphy SP, Fernando R, Gardner L, Ahad T, Moffett A
Immunology 2009 May;127(1):26-39

Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells.

Ivanov A, Beers SA, Walshe CA, Honeychurch J, Alduaij W, Cox KL, Potter KN, Murray S, Chan CH, Klymenko T, Erenpreisa J, Glennie MJ, Illidge TM, Cragg MS
The Journal of clinical investigation 2009 Aug;119(8):2143-59

Extracorporeal photophoresis increases sensitivity of monocytes from patients with graft-versus-host disease to HLA-DR-mediated cell death.

Setterblad N, Garban F, Weigl R, Assier E, Drillat P, Charron D, Dickinson A, Greinix H, Mooney N
Transfusion 2008 Jan;48(1):169-77

Identification of HLA-DR-bound peptides presented by human bronchoalveolar lavage cells in sarcoidosis.

Wahlström J, Dengjel J, Persson B, Duyar H, Rammensee HG, Stevanović S, Eklund A, Weissert R, Grunewald J
The Journal of clinical investigation 2007 Nov;117(11):3576-82

Autophagy promotes MHC class II presentation of peptides from intracellular source proteins.

Dengjel J, Schoor O, Fischer R, Reich M, Kraus M, Müller M, Kreymborg K, Altenberend F, Brandenburg J, Kalbacher H, Brock R, Driessen C, Rammensee HG, Stevanovic S
Proceedings of the National Academy of Sciences of the United States of America 2005 May 31;102(22):7922-7

Identification of HLA-DRB1-bound self-peptides following measles virus infection.

Ovsyannikova IG, Johnson KL, Naylor S, Poland GA
Journal of immunological methods 2005 Feb;297(1-2):153-67

The Mycobacterium tuberculosis 19-kilodalton lipoprotein inhibits gamma interferon-regulated HLA-DR and Fc gamma R1 on human macrophages through Toll-like receptor 2.

Gehring AJ, Rojas RE, Canaday DH, Lakey DL, Harding CV, Boom WH
Infection and immunity 2003 Aug;71(8):4487-97

Interaction of HLA-DR with an acidic face of HLA-DM disrupts sequence-dependent interactions with peptides.

Pashine A, Busch R, Belmares MP, Munning JN, Doebele RC, Buckingham M, Nolan GP, Mellins ED
Immunity 2003 Aug;19(2):183-92

Inhibition of HLA-DR assembly, transport, and loading by human cytomegalovirus glycoprotein US3: a novel mechanism for evading major histocompatibility complex class II antigen presentation.

Hegde NR, Tomazin RA, Wisner TW, Dunn C, Boname JM, Lewinsohn DM, Johnson DC
Journal of virology 2002 Nov;76(21):10929-41

Rheumatoid arthritis (RA)-associated HLA-DR alleles form less stable complexes with class II-associated invariant chain peptide than non-RA-associated HLA-DR alleles.

Patil NS, Pashine A, Belmares MP, Liu W, Kaneshiro B, Rabinowitz J, McConnell H, Mellins ED
Journal of immunology (Baltimore, Md. : 1950) 2001 Dec 15;167(12):7157-68

Humanization and characterization of the anti-HLA-DR antibody 1D10.

Kostelny SA, Link BK, Tso JY, Vasquez M, Jorgensen BH, Wang H, Hall WC, Weiner GJ
International journal of cancer 2001 Aug 15;93(4):556-65

Determination of the HLA-DM interaction site on HLA-DR molecules.

Doebele RC, Busch R, Scott HM, Pashine A, Mellins ED
Immunity 2000 Oct;13(4):517-27

HLA-DR restricted peptide candidates for bee venom immunotherapy.

Texier C, Pouvelle S, Busson M, Hervé M, Charron D, Ménez A, Maillère B
Journal of immunology (Baltimore, Md. : 1950) 2000 Mar 15;164(6):3177-84

HLA-DR-mediated apoptosis susceptibility discriminates differentiation stages of dendritic/monocytic APC.

Bertho N, Drénou B, Laupeze B, Berre CL, Amiot L, Grosset JM, Fardel O, Charron D, Mooney N, Fauchet R
Journal of immunology (Baltimore, Md. : 1950) 2000 Mar 1;164(5):2379-85

Kinetics of T-cell receptor binding by bivalent HLA-DR. Peptide complexes that activate antigen-specific human T-cells.

Appel H, Gauthier L, Pyrdol J, Wucherpfennig KW
The Journal of biological chemistry 2000 Jan 7;275(1):312-21

HLA-G suppresses proliferation of CD4(+) T-lymphocytes.

Bainbridge DR, Ellis SA, Sargent IL
Journal of reproductive immunology 2000 Aug;48(1):17-26

Modulation of the major histocompatibility complex class II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)-DO.

van Ham M, van Lith M, Lillemeier B, Tjin E, Grüneberg U, Rahman D, Pastoors L, van Meijgaarden K, Roucard C, Trowsdale J, Ottenhoff T, Pappin D, Neefjes J
The Journal of experimental medicine 2000 Apr 3;191(7):1127-36

CD4+ tumor-infiltrating lymphocytes in cervical cancer recognize HLA-DR-restricted peptides provided by human papillomavirus-E7.

Höhn H, Pilch H, Günzel S, Neukirch C, Hilmes C, Kaufmann A, Seliger B, Maeurer MJ
Journal of immunology (Baltimore, Md. : 1950) 1999 Nov 15;163(10):5715-22

HLA class II molecules (HLA-DR, -DP, -DQ) on cells in the human CNS studied in situ and in vitro.

Ulvestad E, Williams K, Bø L, Trapp B, Antel J, Mørk S
Immunology 1994 Aug;82(4):535-41

The TAPA-1 molecule is associated on the surface of B cells with HLA-DR molecules.

Schick MR, Levy S
Journal of immunology (Baltimore, Md. : 1950) 1993 Oct 15;151(8):4090-7

Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles.

Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS, Strominger JL
The Journal of experimental medicine 1993 Jul 1;178(1):27-47

Identification of the staphylococcal enterotoxin A superantigen binding site in the beta 1 domain of the human histocompatibility antigen HLA-DR.

Herman A, Labrecque N, Thibodeau J, Marrack P, Kappler JW, Sekaly RP
Proceedings of the National Academy of Sciences of the United States of America 1991 Nov 15;88(22):9954-8

Growth inhibition of Epstein-Barr virus-transformed B cells by anti-HLA-DR antibody L243: possible relationship to L243-induced down-regulation of CD23 antigen expression.

Kabelitz D, Janssen O
Cellular immunology 1989 Apr 15;120(1):21-30

Monoclonal antibodies that distinguish between class II antigens (HLA-DP, DQ, and DR) in 14 haplotypes.

Robbins PA, Evans EL, Ding AH, Warner NL, Brodsky FM
Human immunology 1987 Apr;18(4):301-13

Characterization and expression of the HLA-DC antigens defined by anti-Leu 10.

Chen YX, Evans RL, Pollack MS, Lanier LL, Phillips JH, Rousso C, Warner NL, Brodsky FM
Human immunology 1984 Aug;10(4):221-35

No comments: Submit comment

Supportive validation